Delving into the Latest Updates on Urinary Kallidinogenase with Synapse

Overview

Basic Info

Drug Type

Enzyme

Synonyms

凯力康

Target

KNG1

Mechanism

KNG1 inhibitors(Kininogen-1 inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Brain Infarction

Inactive Indication-

Originator Organization

Techpool Bio-Pharma Co., Ltd.

Active Organization

Techpool Bio-Pharma Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (19 Oct 2005),

Brain Infarction

Regulation-

Login to view timeline

Efficacy and safety of Urinary Kallidinogenase in the treatment of acute ischemic stroke combined with type 2 diabetes mellitus (TK-SEEK): a prospective, multicenter, randomized, double-blind, placebo-parallel controlled study - Efficacy and safety of Urinary Kallidinogenase in the treatment of acute ischemic stroke combined with type 2 diabetes mellitus

Start Date15 Oct 2023

Sponsor / Collaborator-

100 Clinical Results associated with Urinary Kallidinogenase

Login to view more data

100 Translational Medicine associated with Urinary Kallidinogenase

Login to view more data

100 Patents (Medical) associated with Urinary Kallidinogenase

Login to view more data

11

Literatures (Medical) associated with Urinary Kallidinogenase

01 Jan 2023·Computational and Mathematical Methods in Medicine

Retracted: Urinary Kallidinogenase plus rt‐PA Intravenous Thrombolysis for Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Author: Methods in Medicine, Computational and Mathematical ; Methods In Medicine, Computational And Mathematical

[This retracts the article DOI: 10.1155/2022/1500669.].

17 May 2022·Computational and Mathematical Methods in Medicine

Urinary Kallidinogenase plus rt-PA Intravenous Thrombolysis for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Review

Author: Wu, Jiang ; Wu, Jing ; Wang, Le ; Liu, Jinmin

Purpose. This research is aimed at systematically assessing the safety and effectiveness of intravenous thrombolysis (IVT) with rt-PA plus human urinary kallidinogenase (HUK) for acute ischemic stroke (AIS). Methods. The data were obtained through rigorous searching of both domestic and foreign databases from inception to 2021.7.1. Randomized controlled trials (RCTs) were included for the comparison of the efficacy of IVT plus HUK. The Cochrane risk of bias (RoB) tool and Review Manager software 5.3 were responsible for RoB assessment and statistical analyses, respectively. Results. A total of 18 articles were retrieved, including 2676 AIS patients treated with IVT within the time window. The control group used standardized rt-PA IVT, and the test group added HUK. After 14 days of combined application of HUK, the National Institute of Health Stroke Scale (NIHSS) score was significantly better in moderate stroke patients using the combination treatment versus those with IVT alone (

mean difference (MD) = - 3.13

; 95% confidence intervals (CI): -3.40,-2.86;

P < 0.00001

); the NIHSS score was also statistically in severe stroke patients with combined treatment than in those with IVT alone, but the degree of recovery of patients varied greatly. After 90 days of treatment, the NIHSS (

MD = - 1.93

; 95% CI: -2.51,-1.34;

P < 0.00001

) and Barthel index (BI) scores (

MD = 22.23

; 95% CI: 18.96, 25.49;

P < 0.00001

) of patients plus HUK were significantly better than those of patients with IVT alone, with fewer adverse events during treatment (

Relative Risk (RR) = 0.66

; 95% CI: 0.47, 0.92;

P = 0.02

). Conclusions. For AIS patients with IVT within the time window, HUK plus rt-PA IVT could significantly improve the neurological function recovery after 14 days and the quality of life after 90 days and reduce the adverse reactions of IVT. This trial is registered with CRD42021226975.

01 Sep 2020·Journal of International Medical ResearchQ4 · MEDICINE

Efficacy and safety of human urinary kallidinogenase for acute ischemic stroke: a meta-analysis

Q4 · MEDICINE

ArticleOA

Author: Wang, Peize ; Wang, Binglei ; Huang, Yuanxiang ; Zhang, Yue ; Zhang, Xiangjian

Objective Human urinary kallidinogenase (HUK) is a glycoprotein extracted from human urine that is used to treat stroke by triggering positive regulation of the kallikrein–kinin system. Our aim was to evaluate the efficacy and safety of HUK treatment for acute ischemic stroke. Methods We searched the online databases PubMed, Embase, Cochrane Library, Google Scholar, and China National Knowledge Infrastructure (CNKI) for papers published between January 2015 and December 2019. The quality of each trial was assessed using the Cochrane Reviewers’ Handbook. Randomized controlled trials of HUK in patients with acute ischemic stroke were included. Results Sixteen trials with 1326 participants were included. The HUK injection groups had more neurological improvement than the control groups in National Institutes of Health Stroke Scale scores (mean difference, –1.65; 95% confidence interval [CI], –2.12 to –1.71) and clinical efficacy (1.30; 95% CI, 1.21 to 1.41). Subgroup analysis indicated that age may influence heterogeneity. Eleven trials reported adverse effects and there were no significant differences between the control and HUK groups (risk difference, 0.01; 95% CI, –0.02 to 0.04). Conclusions HUK ameliorates neurological symptoms in stroke patients with few adverse effects. Further high-quality, large-scale randomized trials are needed to confirm these results.

100 Deals associated with Urinary Kallidinogenase

Login to view more data